3DBioFibR Secures $3M to Scale Advanced Biopolymer Fiber Manufacturing Platform
3DBioFibR Inc., a trailblazer in the development and manufacturing of advanced biopolymer fibers, has successfully closed a $3 million equity financing round that will fuel its next stage of operational growth and technological advancement. This capital infusion comes on the heels of multiple strategic paid partnerships and collaborative agreements that span a variety of industries, including tissue engineering, medical devices, defense, cosmetics, and performance apparel. These engagements, many of which involve multinational corporations, underscore the growing demand for next-generation biomaterials that are both high-performing and sustainable.
The $3 million financing round included contributions from both new and returning investors. Key participants in the round were AoA Innovation Fund, Build Ventures, Invest Nova Scotia, and Concrete Ventures, all of whom recognize the strategic value and transformative potential of 3DBioFibR’s manufacturing platform. This investment milestone will help the company expand manufacturing capacity, enhance operational infrastructure, and implement ISO 13485 certification standards—a critical requirement for companies supplying materials for regulated medical and therapeutic applications.
“This investment fuels the next phase of our growth,” said Kevin Sullivan, Chief Executive Officer of 3DBioFibR. “It enables us to meet growing demand from our commercial partners and to become a qualified supplier for regulated medical and therapeutic applications. ISO 13485 certification is a key step in delivering clinical-grade fibers at the scale and consistency our partners require. We’re excited to expand our impact across industries that urgently need stronger, more sustainable biomaterials.”
As part of the scale-up strategy, 3DBioFibR plans to construct a state-of-the-art clean room manufacturing facility, which will be essential for producing sterile, medical-grade biopolymer fibers that meet stringent industry and regulatory standards. This expansion aligns with the company’s broader objective to become the preferred supplier of biocompatible fiber solutions for companies developing products for regenerative medicine, wound healing, surgical implants, and a host of other biomedical and industrial applications.
In the past two years, the company has made significant strides by signing multiple paid development agreements with regional and global players across diverse sectors. These collaborations are centered around incorporating 3DBioFibR’s proprietary fibers into a range of applications, including artificial tissues, wearable health devices, protective materials, and cosmetic formulations. The latest funding round ensures that the company is well-positioned to scale production and maintain the high-performance standards that its partners expect.
Patrick Keefe, General Partner at Build Ventures, emphasized the commercial viability of 3DBioFibR’s innovations: “3DBioFibR has accomplished something rare, translating cutting-edge biomaterials science into real commercial traction. They’ve partnered with serious players in global industries and built a manufacturing platform that can deliver fibers at a scale and quality the market hasn’t seen before. This team is setting the benchmark in biopolymer fiber manufacturing, and we’re proud to support their journey.”
Lidija Marušić of Invest Nova Scotia echoed this sentiment, highlighting the regional economic significance and market potential of the company: “As an early investor in 3DBioFibR, Invest Nova Scotia has been active with the company throughout its growth into a unique business that offers novel and unparalleled manufacturing potential for biopolymer applications, representing multibillion-dollar market opportunities. With this latest investment, Invest Nova Scotia looks forward to seeing 3DBioFibR achieve their objectives.”
At the core of 3DBioFibR’s technological edge is its proprietary dry-spinning platform, a revolutionary process that allows for the scalable production of biopolymer fibers with mechanical properties that outperform natural tissue by two to three times. Unlike conventional fiber manufacturing techniques such as wet spinning and electrospinning, which often suffer from limitations in volume, consistency, and cost, 3DBioFibR’s method can produce material at over 3,600 times the scale with superior uniformity. This level of efficiency and quality opens new possibilities in both medical and non-medical fields where strength, biocompatibility, and scalability are essential.
The company currently produces fibers from more than six different biopolymers, each engineered to meet specific application requirements. These include collagen, chitosan, and silk fibroin, among others—materials that are naturally occurring, renewable, and biodegradable. As the global market increasingly seeks sustainable alternatives to synthetic materials, 3DBioFibR is uniquely positioned to meet that demand.
With the newly acquired capital, 3DBioFibR aims to accelerate the commercialization of its fiber solutions, grow its team, and invest further in research and development to expand its biopolymer portfolio. The company is also targeting new partnership opportunities in pharmaceutical delivery systems, bioresorbable textiles, and next-gen personal care products.
Ultimately, 3DBioFibR’s goal is to become a foundational supplier of high-performance biopolymer fibers that enable innovation across sectors that are ripe for transformation. Whether in healing tissues, replacing sutures, fortifying protective gear, or improving consumer health products, the company’s materials promise to deliver strength, safety, and sustainability at scale.
This $3 million raise not only validates 3DBioFibR’s business model but also cements its role as a pioneering force in the biomaterials revolution. As demand for clinical-grade, sustainable fibers continues to grow, 3DBioFibR is strategically positioned to lead the way forward in reshaping material science for the better.
About 3DBioFibR Inc.
3DBioFibR is driving the adoption of biomaterials in regenerative medicine, medical devices, defense, cosmetics, and sustainable textiles. It’s patented dry-spinning technology enables scalable, high-precision manufacturing of advanced biopolymer fibers—delivering superior performance at industrial scales. By collaborating with industry leaders, 3DBioFibR is unlocking transformative applications for strong, lightweight, and biocompatible materials across some of the world’s most demanding sectors.
